Impact Biomedical (IBO) EBIT Growth (1y) (2023 - 2026)
Powered by 
Analysis
Impact Biomedical (IBO) EBIT Growth (1y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 32.30% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -520.13% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 8.32% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 19.82% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 145.20% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 10.14% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1,528.74% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -563.67% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 | 39.12% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.12% |
| Mar 31, 2026 | -126.63% |
| Sep 30, 2025 | 15.88% |
| Jun 30, 2025 | -84.19% |
| Mar 31, 2025 | -31.00% |
| Dec 31, 2024 | -2,202.99% |
| Sep 30, 2024 | -4.55% |
| Jun 30, 2024 | 37.90% |
| Mar 31, 2024 | 3.99% |
| Dec 31, 2023 | -10.37% |
| Sep 30, 2023 | -21.26% |
| Jun 30, 2023 | -34.40% |